SCYX
Price:
$4.23
Market Cap:
$26.60M
SCYNEXIS, Inc. is a biotechnology firm based in the U.S. dedicated to developing therapies for fungal infections. The company's flagship product, BREXAFEMME (ibrexafungerp tablets), has received approval for the treatment of vulvovaginal candidiasis (VVC). Furthermore, SCYNEXIS is progressing ibrexafungerp, its leading drug candidate, as both an oral and intravenous medicine designed to address various fungal conditions, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and challenging refractory invasive fungal infections. Ibrexafungerp has successfully completed the Phase 3 CANDLE study, which evaluated its effectiveness in preventing recurrent VVC. SCYNEXIS has also e...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2014-05-02
Stock Exchange
NASDAQ
Ticker
SCYX
According to SCYNEXIS, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.10. This represents a change of 89.29% compared to the average of -0.58 of the last 4 quarters.
The mean historical PE Ratio of SCYNEXIS, Inc. over the last ten years is -1.94. The current -1.10 PE Ratio has changed 5.56% with respect to the historical average. Over the past ten years (40 quarters), SCYX's PE Ratio was at its highest in in the March 2024 quarter at 43.73. The PE Ratio was at its lowest in in the September 2021 quarter at -58.29.
Average
-1.94
Median
-1.86
Minimum
-4.90
Maximum
1.59
Discovering the peaks and valleys of SCYNEXIS, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 229.53%
Maximum Annual PE Ratio = 1.59
Minimum Annual Increase = -273.24%
Minimum Annual PE Ratio = -4.90
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -3.67 | 33.04% |
| 2024 | -2.76 | -273.24% |
| 2023 | 1.59 | -250.39% |
| 2022 | -1.06 | -78.39% |
| 2021 | -4.90 | 229.53% |
| 2020 | -1.49 | 56.40% |
| 2019 | -0.95 | -43.99% |
| 2018 | -1.70 | -31.49% |
| 2017 | -2.48 | 22.29% |
| 2016 | -2.02 | -12.54% |
The current PE Ratio of SCYNEXIS, Inc. (SCYX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.61
5-year avg
-2.16
10-year avg
-1.94
SCYNEXIS, Inc.’s PE Ratio is greater than Talphera, Inc. (-2.60), less than Cosmos Health Inc. (-0.47), less than Cadrenal Therapeutics, Inc. Common Stock (-0.75), greater than Exicure, Inc. (-1.81), greater than Klotho Neurosciences, Inc. (-1.98), less than CollPlant Biotechnologies Ltd. (-0.35), less than Sonnet BioTherapeutics Holdings, Inc. (-0.32), less than Nexalin Technology, Inc. (-1.03), greater than NeurAxis, Inc. (-10.07), greater than NeuroSense Therapeutics Ltd. (-2.87),
| Company | PE Ratio | Market cap |
|---|---|---|
| -2.60 | $17.92M | |
| -0.47 | $13.04M | |
| -0.75 | $10.61M | |
| -1.81 | $17.72M | |
| -1.98 | $20.08M | |
| -0.35 | $4.14M | |
| -0.32 | $8.43M | |
| -1.03 | $8.87M | |
| -10.07 | $82.98M | |
| -2.87 | $18.13M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SCYNEXIS, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like SCYNEXIS, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is SCYNEXIS, Inc.'s PE Ratio?
How is the PE Ratio calculated for SCYNEXIS, Inc. (SCYX)?
What is the highest PE Ratio for SCYNEXIS, Inc. (SCYX)?
What is the 3-year average PE Ratio for SCYNEXIS, Inc. (SCYX)?
What is the 5-year average PE Ratio for SCYNEXIS, Inc. (SCYX)?
How does the current PE Ratio for SCYNEXIS, Inc. (SCYX) compare to its historical average?